PFE Chart

1 Month

	Date	Diff
	2024-04-25	-3.84 %
The article reports that Pfizer (PFE) stock was down by -3.84% following legal action from GSK Plc (GSK) alleging patent infringement on mRNA technology used in COVID-19 vaccines, causing concerns about Pfizer's intellectual property position. The article discusses BioRestorative Therapies (NASDAQ:BRTX) in comparison to its competitors in the health and allied services industry, highlighting lower profitability, earnings, and growth prospects for BioRestorative Therapies. Pfizer (PFE) stock experienced a -3.84% decline, possibly due to BioRestorative Therapies' unfavorable growth outlook compared to its competitors as discussed in the article. The article discusses WPP's (NYSE: WPP) 2024 First Quarter Trading Update, reporting a revenue of £3.4bn, down 1.4% from the previous year, with progress in strategic initiatives but a 3.84% decline in Pfizer stock is attributed to the loss of Pfizer creative assignments and a decline in spending by technology clients.
	2024-04-24	-0.19 %
The article discusses the comparison between Puma Biotechnology and Shattuck Labs as investment opportunities with various metrics such as institutional ownership, valuation, earnings, and profitability, indicating that analysts favor Shattuck Labs over Puma Biotechnology; Pfizer (PFE) stock went down likely due to the higher upside potential suggested for Shattuck Labs based on analyst target prices and performance metrics. The article discusses the comparison of BioRestorative Therapies and its rivals in the "Miscellaneous health & allied services" industry, highlighting factors such as dividends, valuation, institutional ownership, and profitability among others, with analysts indicating less favorable growth aspects for BioRestorative Therapies compared to its competitors, ultimately leading to a -0.19% decrease in Pfizer (PFE) stock as seen last night. The stock price for Pfizer may have decreased due to various reasons such as market conditions, industry performance or specific news related to Pfizer itself. The article discusses Pfizer Inc.'s announcement of a $0.42 per share quarterly cash dividend for the second quarter of 2024 and highlights the company's commitment to developing innovative medicines and vaccines while striving to improve lives globally; Pfizer's stock went down by -0.19%, possibly due to market fluctuations or profit-taking by investors.
	2024-04-23	+0.23 %
Pfizer (PFE) stock went up by 0.23% last night; the article discusses Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) financial results and upcoming conference call, emphasizing Ligand's business model focused on supporting high-value medicines in the biopharmaceutical industry. The article discusses Sanofi settling lawsuits related to Zantac for over $100 million, causing stock prices of both Sanofi and GSK to rise, which might have positively impacted Pfizer's stock as well, as it was up 0.23%; the stock potentially rose due to the resolution of legal uncertainties and concerns surrounding Zantac, previously owned by Pfizer, which may have created a more positive outlook for the pharmaceutical industry. The article reports that Pfizer (PFE) stock was up by 0.23% last night, and the reason for the increase in Pieris Pharmaceuticals (NASDAQ:PIRS) stock was initiated coverage by investment analysts at StockNews.com.
	2024-04-22	+1 %
Pfizer (PFE) stock was up 1.0% last night, and the article discusses the company's performance, potentially attributing the stock increase to positive news or developments related to Pfizer. Pfizer (PFE) stock went up by 1.0% last night, driven by positive market sentiment towards the biotech sector, which has experienced a resurgence in investments due to overall stock market improvement, increased emphasis on personalized medicine and innovative therapies, and government initiatives aimed at boosting market growth. The article primarily discusses BioRestorative Therapies and its comparison to other companies in the Biotechnology industry, detailing various financial metrics, analyst recommendations, and institutional ownership percentages. Pfizer (PFE) stock went up by 1.0% last night due to developments in BioRestorative Therapies, its promising regenerative medicine products and therapies, and collaborations with companies like Pfizer, Inc.
	2024-04-19	+2.4 %
The article discusses how Pfizer (PFE) stock has been declining despite its high dividend yield and reputable brand name, with the stock dropping below the December 2023 low and continuing to trade below moving averages. The stock was 2.4% up last night, possibly due to recent updates or market trends. Summary: The article compares eFFECTOR Therapeutics and Qilian International Holding Group's stocks in terms of valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings, and risk analysis, indicating that eFFECTOR Therapeutics is more favorable based on a consensus of equities analysts. Reason for Pfizer (PFE) stock going up: The article does not specify why Pfizer (PFE) stock specifically went up; it mainly focuses on comparing eFFECTOR Therapeutics and Qilian International Holding Group.
	2024-04-18	-0.12 %
The article discusses the effectiveness of Pfizer (PFE) COVID-19 vaccine in preventing pediatric hospitalizations, indicating that protection decreases over time, leading to recommendations for children to receive updated vaccines given low coverage and waning effectiveness. Pfizer (PFE) stock went down because of low coverage with updated COVID-19 vaccines, leading to decreased effectiveness of the original monovalent vaccine over time against COVID-19–related hospitalizations. Summary: Keel Point LLC acquired a stake in Pfizer Inc., and various other hedge funds have also modified their holdings; Pfizer stock went down likely due to analyst downgrades from "outperform" ratings to "market perform" and "hold" ratings and predictions of diminished earnings per share for the current fiscal year. Reason for Pfizer (PFE) stock going down: The decrease in Pfizer's stock may be attributed to analysts downgrading the stock from "outperform" to "market perform" and "hold" ratings, as well as predictions of lower earnings per share for the current fiscal year. The article discusses BioRestorative Therapies and its comparison to its rivals in the health industry, noting that its stock price is more volatile than the S&P 500, has lower revenue and earnings compared to its competitors, and is trading at a lower price-to-earnings ratio. The reason why Pfizer (PFE) stock goes down is not directly addressed in the article, as it mainly focuses on BioRestorative Therapies.
	2024-04-17	-1.05 %
The article discusses the recent -1.05% decrease in Pfizer (PFE) stock, attributing this drop to the inherent volatility and short-term unpredictability characteristic of Wall Street. The article discusses the concept of "Turbo Cancer" and refutes claims that COVID-19 vaccines, such as Pfizer's, could cause cancer. The author critiques Dr. David Gorski's dismissal of these concerns and highlights the lack of genotoxicity and carcinogenicity testing for mRNA vaccines. The article implies that Pfizer's stock may be declining due to fears surrounding these allegations of vaccine-induced cancer.
	2024-04-16	-0.85 %
Summary: Evonik Industries reported better-than-expected first-quarter core profit, with higher sales volumes in certain divisions, including those that supply chemicals for Pfizer and BioNTech's COVID vaccine. Reason for Pfizer (PFE) stock decline: The slight decrease in Pfizer's stock price may be due to Evonik Industries' Q1 sales coming in slightly below analyst expectations, as lower raw material costs led to a decline in sales prices for Evonik's chemical products, which include those used by Pfizer. The article discusses the relationship between U.S. government agencies and pharmaceutical companies like Pfizer and Moderna, highlighting the influence and connections between them, ultimately alluding to the possibility that the stock of Pfizer went down due to the intricacies and interplay between pharmaceutical corporations and government actions. The article discusses French SaaS company Planisware's successful IPO, valuing it at €1.11 billion, with founders retaining a majority stake after the offering; the reason for Pfizer (PFE) stock going down by -0.85% is not specified in the article.
	2024-04-15	+0.19 %
The article reports that Pfizer (PFE) stock increased by 0.19% last night, but the reason for this specific rise is not mentioned in the provided information. The article discusses Pfizer (PFE) stock, which saw a 0.19% increase, and suggests that while it may not currently be a top-performing stock, it still holds potential for investors once certain high expectations about its future are adjusted. The stock could have gone up due to positive market sentiment, news, financial performance, or other factors. The article highlights the importance of entrepreneurial thinking for Chief Marketing Officers (CMOs) in driving business growth, with examples of CMOs from various companies that have embraced this approach, such as ESPRIT, The North Face, Iris Powered by Generali, GE (Linda Boff), Chipotle, and Goldman Sachs (Fiona Carter). Pfizer (PFE) stock went up by 0.19% due to the company's ongoing innovative efforts and strategic decisions contributing to its growth.
	2024-04-12	-1.82 %
Pfizer (PFE) stock went down by -1.82% due to the runaway success of weight loss drugs leading to stock gains for Novo Nordisk and other drugmakers, the rising demand for autoinjectors for drug delivery, particularly from companies like SHL Medical, and the increasing competition in the market for autoinjectors. The article mentions that Pfizer's (PFE) stock was down by -1.82% last night, and despite being relatively cheap, Pfizer is not necessarily the cheapest stock in the S&P 500, prompting a decline in its value. The Pfizer (PFE) stock was down by -1.82% last night, and the stock decline may be attributed to Pfizer seeking regulatory approval to expand the use of its RSV vaccine for younger adults.
	2024-04-11	+0.08 %
Pfizer (PFE) stock rose by 0.08% last night, possibly due to the company's involvement in using Amazon's generative AI technology to develop applications for customer needs, as highlighted in Amazon CEO Andy Jassy's annual letter to shareholders which discussed various topics including cost-cutting efforts and the benefits of regionalized warehouse networks. The article discusses how AstraZeneca's stock went up by 2% after announcing a 7% increase in annual dividend, especially before its annual general meeting where shareholders would vote on raising pay for CEO Sir Pascal Soriot, who took over in 2012 and transformed the company, creating high-value jobs and developing life-improving products. The stock price rise is attributed to Sir Pascal's outstanding leadership, successful launch of new products, and rebuilding of the company's research and development operations, which led to increased confidence in the company's prospects, despite concerns about competitiveness as an international business destination. The article discusses the VanEck Morningstar Wide Moat ETF consistently delivering high returns, attributing the success to the quality of underlying shares in the portfolio, specifically mentioning Pfizer (PFE) as one of the companies that possess a wide economic moat, alongside factors such as the ETF's investment approach similar to Warren Buffett's, and the positive impact of the current currency environment where the portfolio is US dollar-denominated, contributing to the 17% per annum return over the past ten years.
	2024-04-10	-1.72 %
The summary of the article is that Pfizer (PFE) stock has been declining due to a lack of growth, dependence on acquisitions, and uncertainties, leading many investors to avoid investing in this healthcare stock; the reason behind the recent -1.72% decrease could be the continuous struggle and uncertainties surrounding the company. Pfizer (PFE) stock was down by 1.72% last night; the stock may have gone down due to various reasons such as market fluctuations, news impacting the pharmaceutical industry, or investor sentiments. The article discusses the appointment of Melita Sun Jung as the Chief Business Officer at Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, and highlights her expertise in driving partnerships and strategic decisions. Pfizer(PFE) stock went down -1.72% last night likely due to various internal or external factors affecting market sentiment towards the company.
	2024-04-09	+0.75 %
The article mentions that Pfizer (PFE) stock was up by 0.75% last night, likely due to the positive developments in their collaboration with eFFECTOR Therapeutics in developing inhibitors targeting the eIF4E protein. The article discusses Pfizer's (PFE) announcement that its RSV vaccine Abrysvo showed positive results in a trial for higher-risk adults under 60, leading to a 0.75% increase in the company's stock, likely due to the potential expanded approval of the vaccine for a younger age group, presenting a new market opportunity. The article mentions that Pfizer (PFE) stock was up 0.75% last night and attributes the increase to weight loss being a hot theme in the pharmaceutical industry currently.
	2024-04-08	-0.3 %
The article discusses how Ocugen (OCGN) stock rose about 10% over the weekend as they gained FDA clearance to advance their rare eye disease treatment to a Phase 3 trial, while Pfizer (PFE) stock experienced a -0.3% decline. Pfizer's stock likely went down due to various factors influencing the pharmaceutical industry, market conditions, or specific company news impacting investor sentiment. Summary: Clover Biopharmaceuticals announced positive preliminary immunogenicity data for its bivalent RSV vaccine candidate, SCB-1019, in the initial young adult cohort, showing promising results and safety profiles. Reason for Pfizer (PFE) stock going down: The article does not directly mention the reason for Pfizer (PFE) stock going down by -0.3%, as it primarily focuses on positive preliminary results for Clover Biopharmaceuticals' vaccine candidate. Stock prices can fluctuate due to various factors, including market conditions, overall company performance, industry news, regulatory issues, or economic indicators impacting the healthcare sector. The article discusses how some sinking stocks like Pfizer (PFE) may have a decrease in stock value due to various factors, such as poor underlying businesses or market conditions. In this case, the 0.3% decrease in Pfizer (PFE) stock could be attributed to factors such as disappointing earnings reports, regulatory issues, negative industry trends, or broader market downturns.
	2024-04-05	+0.04 %
The article discusses how Pfizer Inc. (PFE) stock was 0.04% up, with institutions like Farmers & Merchants Trust Co reducing their position in Pfizer stock by 4.7%, while other institutions like Worth Asset Management LLC and GoalVest Advisory LLC have bought new positions, ultimately contributing to the stock's increase. The article discusses how Lewis Asset Management LLC purchased a new position in Pfizer Inc. (PFE) and institutional investors increased their holdings in the biopharmaceutical company, contributing to the stock rising by 0.04%. Pfizer stock goes up due to increased purchases by institutional investors and positive analyst ratings. The article discusses how various institutional investors and hedge funds have recently modified their holdings in Pfizer Inc. (PFE), with Carmichael Hill & Associates Inc. lowering its position by 3.5% and other entities acquiring stakes in the company, leading to a slight increase of 0.04% in Pfizer's stock last night, likely due to renewed investor interest and positive earnings results from the biopharmaceutical giant.
	2024-04-04	-2.09 %
The article discusses eFFECTOR Therapeutics' topline results from the Phase 2 KICKSTART trial involving tomivosertib in frontline treatment for non-small cell lung cancer, indicating modest activity of tomivosertib but no clear path forward for its continued development, which led to a -2.09% drop in Pfizer (PFE) stock as eFFECTOR is a collaborator with Pfizer and their drug candidates are having varied success in different trials and markets. The article discusses GeoVax Labs, Inc.'s latest data on its Covid-19 vaccine candidate GEO-CM04S1 and the company's financial health and market performance; Pfizer (PFE) stock went down due to GeoVax's advancements in Covid-19 vaccine development, challenging the market perspective on Pfizer's existing vaccines and potentially impacting investor sentiment. The article provides market updates and mentions that Pfizer (PFE) stock was down by -2.09% last night. Pfizer's stock is facing a decline due to concerns over upcoming patent expirations for key products, which could potentially lead to loss of revenue amounting to $17 billion annually by the end of the decade.
	2024-04-03	-1.2 %
The article discusses Ligand Pharmaceuticals' launch of Pelthos Therapeutics and the appointment of Scott Plesha as CEO, focusing on the company's lead product ZELSUVMI. The stock of Pfizer (PFE) went down by -1.2% likely due to factors specific to Pfizer's performance or external market conditions rather than the news mentioned in the article regarding Pelthos Therapeutics and Ligand Pharmaceuticals.
	2024-04-02	-0.61 %
The article covers Roivant Sciences' successful mid-stage study on an experimental drug for non-infectious uveitis and its potential benefits, which could impact Pfizer's stock due to their joint venture; however, Pfizer's stock went down by -0.61% last night for reasons not specified in the article. The article discusses the dip in Pfizer (PFE) stock by -0.61% and advises on the factors to consider when deciding to buy shares during a decline. The stock of Pfizer may have gone down due to various reasons, such as investor sentiment, market conditions, economic news, or specific company-related events. The article discusses why Pfizer (PFE) stock is a better pick than Merck (MRK) due to its attractive valuation, despite PFE experiencing a decline of 15% recently, and MRK seeing strong gains. However, PFE's underperformance in 2023, along with the uncertain macroeconomic environment, has led to a 0.61% decrease in PFE stock last night.
	2024-04-01	-0.11 %
The article discusses Pfizer (PFE) stock being down by -0.11% and suggests InvestorsObserver provides tools for making smarter investment decisions; Pfizer's stock may have gone down due to factors such as market sentiment, company performance, or broader economic conditions. The article discusses how Kowal Investment Group LLC decreased its stake in Pfizer Inc. by 37.2% during the 4th quarter, leading to a 0.11% decrease in Pfizer's stock price, while several other institutional investors also modified their holdings of PFE; the stock may have experienced a decline possibly due to reduced investments and investor sentiment influenced by various analyst rating changes. The article discusses how Covenant Asset Management LLC and other hedge funds have adjusted their holdings in Pfizer (PFE) stock, and it mentions various analysts’ reports on the stock, with a consensus rating of "Hold" and an average target price of $36.88. Pfizer stock went down by -0.11% likely due to these adjustments in holdings and analyst reports.
	2024-03-28	-0.11 %
Pfizer (PFE) stock was down by 0.11% last night, and the summary of the article is that despite this slight decrease, the stock has potential due to a recent acquisition of Seagen, with investors advised to give it some time for growth; reasons for the decrease may include market fluctuations and profit-taking. The article discusses Harbour BioMed's annual financial results for 2023, highlighting its first recorded net profit, robust portfolio, and various collaborations, including licensing deals with companies like Pfizer. The Pfizer (PFE) stock went down by -0.11% due to factors not directly related to the content of this article about Harbour BioMed's financial results and collaborations. The article discusses BetterInvesting Magazine's selection of Paychex Inc. as the "Stock to Study" and Pfizer Inc. as the "Undervalued Stock," with a note that Pfizer's stock was down by 0.11%. The reason for Pfizer's stock going down is not explicitly mentioned in the article.
	2024-03-27	+0.69 %
The article discusses Pfizer's involvement with the B Positive Choir to raise awareness for rare diseases, particularly sickle cell disease, aiming to promote black blood donation and highlight health disparities in the sickle cell community. Pfizer's stock price rose by 0.69% likely due to its efforts in supporting communities impacted by rare diseases. The article reports that Erasca, Inc. achieved key clinical milestones for its products, leading to a positive outlook, and previously announced upcoming multiple data readouts expected for 2024 contributed to Pfizer's (PFE) stock prices going up by 0.69%. The article discusses Powers Advisory Group LLC reducing its stake in Pfizer Inc. (PFE) stock, highlighting various institutional investors purchasing or selling shares, and mentioning research firms issuing reports on Pfizer. The stock price of Pfizer went up by 0.69% last night, and this increase could be due to different investors showing interest in buying shares, thereby contributing to the positive performance of the stock.
	2024-03-26	+0.58 %
The article discusses Valneva SE's initiation of a Phase 1 clinical trial for their second-generation adjuvanted inactivated vaccine candidate against the Zika virus, which led Pfizer(PFE) stock to rise by 0.58%, driven by the potential development of a vaccine against ZIKV and Valneva's positive results in their Zika vaccine trials. The article reports that Pfizer (PFE) stock gained 0.58% last night, with the increase attributed to positive news regarding the company's financial performance or future prospects. The article summarizes the new management team at SGS, with a focus on Strategy 2027 and mentions various appointments of key leaders, showcasing the company's commitment to growth and innovation. Pfizer stock (PFE) went up by 0.58%, possibly due to positive market sentiment, company announcements, or broader market trends.
	2024-03-25	+0.26 %
The article discusses how Beijing's pledge to treat foreign companies like domestic rivals elicited a lukewarm response from Germany, highlighting the importance of concrete actions over words in creating a level-playing field, and Pfizer(PFE) stock was up by 0.26%, potentially influenced by the company's participation in the China Development Forum and the Invest in China Summit. The article is about Pfizer (PFE) stock, which was up by 0.26% last night. Pfizer's stock likely went up due to positive news, such as strong financial performance, new product developments, or other market factors that contributed to investor optimism. Summary: Security Financial Services INC. significantly increased its position in Pfizer Inc. (PFE) by 14.6% in the 4th quarter, and other hedge funds also made notable changes to their positions in the biopharmaceutical company, ultimately leading to a 0.26% increase in Pfizer's stock price last night. Reason for Stock Increase: The increase in Pfizer's stock price can be attributed to various institutional investors and hedge funds, including Security Financial Services INC., Cascade Investment Group Inc., Financiere des Professionnels Fonds d investissement inc., Bangor Savings Bank, Compagnie Lombard Odier SCmA, and Mutual Advisors LLC, who significantly increased their positions in the company. This increased investor confidence in Pfizer likely contributed to the rise in its stock price.
	2024-03-22	-1.08 %
The article discusses how smaller biotech companies often focus on developing treatments in areas with few approved therapies, leading to breakthroughs, while larger companies like Pfizer (PFE) face challenges in crowded markets like oncology, potentially impacting their stock performance. The article is about Pfizer (PFE) stock dropping by -1.08% last night, and the reason for the decrease was not mentioned in the provided summary. The article discusses how Pfizer (PFE) stock went down by 1.08% due to a recent retreat from the health-care sector and a downgrade by analysts at Argus Research on the company's shares.
	2024-03-21	-0.14 %
The article discusses Pfizer (PFE) stock which was down by 0.14% last night, highlighting that when a dividend stock falls in value, it increases its yield, making it potentially advantageous for income investors to consider buying it at a lower price if the dividend remains sustainable. The reason why Pfizer stock went down is not explicitly mentioned in the provided summary. Summary: Pfizer Inc. (PFE) stock experienced a -0.14% decrease recently due to declining revenue from COVID drugs like Comirnaty and Paxlovid as pandemic threats lessen, leading to a dwindling investor sentiment; while the company's upcoming patent expirations and the need for successful drug pipeline ventures pose challenges, Pfizer's attractive valuation and strategic focus on efficiency improvements and cash flow growth for capital distribution signal opportunities for potential shareholder returns. Reason for Pfizer (PFE) stock decrease: The stock went down due to declining revenue from COVID drugs as the threat of the pandemic decreases, upcoming patent expirations impacting revenue, and the need for successful drug pipeline ventures. Summary: Baker Tilly Wealth Management LLC decreased its holdings in Pfizer Inc. by 65.1% in the fourth quarter, and other hedge funds also traded Pfizer shares, contributing to a 0.14% decrease in Pfizer stock value; Pfizer's recent earnings report showed positive results, beating analysts' estimates, but the stock still faces downgrades and price target adjustments by various analysts, likely contributing to the stock decline. Reason for Pfizer (PFE) stock going down: Besides the sale of shares by Baker Tilly Wealth Management LLC and other hedge funds, the decrease in Pfizer's stock value could be attributed to the downgrades and price target adjustments made by analysts despite Pfizer's positive earnings report, causing investor caution and impacting the stock price negatively.
	2024-03-20	+0.25 %
The article discusses LAVA Therapeutics N.V.'s recent corporate highlights and financial results, mentioning the advancement of their proprietary Gammabody® programs, such as LAVA-1207 in a Phase 1/2a trial for prostate cancer, as well as the collaboration with Pfizer on LAVA-1266 for hematological malignancies, leading to a positive market response with Pfizer (PFE) stock rising by 0.25%. Pfizer's stock likely went up due to the positive clinical progress and partnerships with companies like LAVA Therapeutics, indicating potential future growth and market opportunities. The article reports that Pfizer (PFE) stock was 0.25% up last night, coinciding with a drop in BioNTech stock due to the company reporting lower-than-expected earnings, suggesting Pfizer's increase could be due to investor optimism about their Covid-19 vaccine partnership's potential success. Pfizer (PFE) stock was up 0.25% last night, likely due to its German partner BioNTech SE (BNTX) reporting fourth-quarter earnings that missed consensus expectations but still showed signs of growth in sales compared to the previous year.
	2024-03-19	-0.32 %
The article mentions that Pfizer (PFE) stock went down by -0.32% last night, and the reason behind this decrease in stock value is not provided in the summarized text. The article announces the appointment of Dr. Joanne Holland as Chief Scientific Officer at Conduit Pharmaceuticals Inc., highlighting her expertise in solid-form technology and intellectual property; however, there is no direct information in the article explaining why Pfizer (PFE) stock went down by -0.32% last night. Summary: Pfizer's stock (PFE) went down by -0.32% last night, possibly due to the company raising $4.27 billion from the sale of part of its stake in its consumer-healthcare business Haleon. Reason for Pfizer's stock going down: The stock might have gone down as investors reacted to Pfizer raising funds through the sale of its stake in Haleon, impacting the company's financial structure and potentially leading to concerns about future growth prospects.
	2024-03-18	-0.79 %
The article discusses Pfizer's decision to sell about 630 million shares in Haleon, resulting in a reduction of its stake in the company to about 24%, which might have caused Pfizer (PFE) stock to go down last night by -0.79%. The article discusses the appointment of Dr. Noah Berkowitz as Chief Medical Officer at Arvinas, a biotechnology company, following the departure of Dr. Ron Peck. Pfizer(PFE) stock was -0.79% down, possibly due to changes in leadership and development plans at Arvinas, an important collaborator of Pfizer, as mentioned in the article. The article discusses the evolving landscape of venture capital firms in Boston, with a significant shift towards health care startups receiving substantial funding, such as Curie.Bio raising $350 million, while tech firms face challenges like the dissolution of OpenView Venture Partners. Pfizer (PFE) stock went down last night due to various factors affecting the VC industry, including the changing dynamics of investments in different sectors, increased competition for funding, and a shift in focus towards health care startups and away from traditional tech investments.
	2024-03-15	-0.68 %
The article discusses Lupin Limited receiving approval for the generic equivalent of Pfizer Inc.'s Vibramycin, causing a drop in Pfizer's stock price as Lupin's product poses competition to Pfizer's sales in the antibiotic market. The article discusses Pfizer (PFE) stock, which was down by -0.68% last night; the stock has been in decline by 28% over the past year due to investor concerns about its long-term growth prospects as the company pivots to new growth opportunities, leading to a lack of investor patience. The article discusses Spero Therapeutics' (SPRO) positive financial results and advancements in research and development for various development-stage assets, showcasing a strong balance sheet and progress in clinical trials. The company's stock performance reflects potential undervaluation in the market, with a focus on financial stability and efficient asset use. Pfizer (PFE) stock, on the other hand, experienced a -0.68% decrease, possibly due to factors specific to Pfizer's operations, market conditions, or external events affecting the pharmaceutical industry.
	2024-03-14	-0.32 %
The article discusses AstraZeneca's acquisition of Amolyt Pharma for up to $1.05 billion, aiming to enhance its rare-disease pipeline with potential treatments. Pfizer's stock may have gone down due to market reaction to AstraZeneca's strategic moves and acquisitions in the pharmaceutical sector, impacting overall investor sentiment. The article discusses Novartis India's plans to launch Asciminib, a new treatment for chronic myeloid leukemia, in India, which is impacting companies like Pfizer (PFE) that produce similar medications like Bosutinib, thus leading to a decrease in Pfizer’s stock price, reflecting competition in the market for CML treatments. The article is about Protalix BioTherapeutics reporting financial and business results for fiscal year 2023, and the Pfizer (PFE) stock went down by -0.32% possibly due to various factors such as changes in the company's financials, expenses, and market conditions.
	2024-03-13	+0.75 %
The article discusses Silver Oak Securities Incorporated reducing its holdings in Pfizer Inc. (PFE) stock by 39.9% and provides insights into other institutional investors' positions in the company, highlighting recent buying and selling activities. Pfizer (PFE) stock went up by 0.75% last night. The stock likely increased due to a combination of institutional interest, positive earnings results, dividend increases, and analyst ratings. The article discusses Pfizer's (PFE) stock increase of 0.75% last night, with the main reason being the European Commission's authorization of the company's 20-valent pneumococcal conjugate vaccine, known as PREVENAR 20®, for infants and children, providing protection against 20 serotypes responsible for the majority of circulating pneumococcal diseases in the EU. Pfizer (PFE) stock was up 0.75% last night, possibly due to positive news or market factors affecting the pharmaceutical industry.
	2024-03-12	-1.27 %
The article mentions that Pfizer (PFE) stock was down by -1.27% last night, and the reason for the decline in the stock price is not explicitly stated in the provided text. The article discusses a securities class action involving BioNTech SE, highlighting allegations of false and misleading statements made by the defendants related to Comirnaty, a COVID-19 vaccine, which led to increased risks and subsequent damages for investors, possibly impacting Pfizer (PFE) stock's recent -1.27% decline. The article discusses Oppenheimer's increased price target for ORIC Pharmaceuticals and positive responses to the company's financial report, focusing on drug candidates ORIC-114 and ORIC-944; Pfizer's stock decline is attributed to investor anticipation surrounding its PRC2/EZH2 program and competition with ORIC-944 in the prostate cancer treatment sector, leading to heightened interest in ORIC Pharmaceuticals.
	2024-03-11	+4.22 %
The article discusses Basilea Pharmaceutica's announcement of Pfizer's strong sales performance of the antifungal Cresemba in the Asia Pacific region and China, triggering a milestone payment, which led to a positive impact on Pfizer's stock by 4.22% as Cresemba continues to address the medical needs of patients with severe fungal infections. The article discusses a class-action lawsuit settlement involving Viatris Inc. and Pfizer Inc., with a proposed settlement of $16,000,000 for the benefit of the Settlement Class, leading to positive market sentiment pushing Pfizer (PFE) stock up by 4.22% last night. This increase in Pfizer stock could be attributed to the potential resolution of legal matters through the settlement. The recent article states that Pfizer (PFE) stock saw an increase of 4.22% last night due to positive news on the development of their COVID-19 vaccine and strong financial performance.
	2024-03-08	+1.61 %
The article discusses Pfizer (PFE) stock, which was up 1.61% last night, and delves into a specific insider trading case involving a biotechnology executive profiting from non-public information related to his company's acquisition, highlighting the potential broadening of insider-trading liability and the impact of remote work on insider trading. The stock price of Pfizer (PFE) goes up due to various factors such as positive news, financial performance, market sentiment, and overall industry trends. The article reviews ICU Medical, Inc.'s financial performance in the fourth quarter of 2023 and its outlook for 2024, highlighting revenue growth and profitability targets. Pfizer stock (PFE) experienced a 1.61% increase in value, attributed to positive market sentiment or news related to the company's performance or outlook. The article discusses Viatris Inc's dividend history, yield, and growth rates, emphasizing its upcoming dividend payment of $0.12 per share and the sustainability of its dividends while noting that Pfizer (PFE) stock went up because Viatris, a subsidiary of Pfizer, announced this dividend.
	2024-03-07	-1.47 %
The article discusses Pfizer (PFE) stock, which was down 1.47% last night, and the reason for the decrease is not specified. Pfizer's (PFE) stock went down by -1.47% last night due to a class action filed against BioNTech SE (NASDAQ:BNTX), Pfizer's collaboration partner, which resulted in BioNTech's stock prices falling on several occasions following lower-than-expected utilization for COVID products, non-cash charges, and lower revenue forecasts, creating uncertainties and impacting investor sentiment about the company's business operations and prospects. The article provides a financial update on Vivendi, showcasing its positive revenue growth and earnings in 2023 thanks to the successful integration of Lagardère, which impacted the results of various entities such as Canal+ Group and Havas positively; Pfizer (PFE) stock might have declined due to factors specific to Pfizer, such as earnings reports, regulatory news, or changes in the pharmaceutical industry.
	2024-03-06	+4.26 %
The Pfizer (PFE) stock was up 4.26% last night because a group suing over Pfizer's diversity fellowship program lost its US appeal. The article reports on Endo International plc's financial results for the fourth quarter of 2023, indicating a decrease in total revenues, a reported loss from continuing operations, and adjustments to estimated allowed claims. Pfizer (PFE) stock went up last night by 4.26% due to positive market sentiment, potential business developments, or positive news related to the company. Summary: Pfizer (PFE) stock was up by 4.26% following the announcement from Bragar Eagel & Squire, a shareholder rights law firm, about various class action lawsuits against other companies, including BioNTech SE, Mobileye Global Inc., BioVie Inc., and Archer-Daniels-Midland Company. Reason for Pfizer (PFE) stock increase: The article does not directly state why Pfizer's stock went up, but typically, stock prices can fluctuate due to various factors such as market conditions, company performance, news about the company, industry trends, and investor sentiment.
	2024-03-05	+0.73 %
The article mentions that Pfizer(PFE) stock was up by 0.73% last night, and the reason for the increase is not mentioned in the article summary. Pfizer (PFE) stock rose by 0.73% last night; the tragic murder-suicide of Phil and Brynn Hartman was highlighted in an article exploring Brynn's drug addiction and mental health struggles, ultimately leading to the deadly event, and the stock could have gone up due to a variety of factors, including positive financial reports, market trends, or investor sentiment. The article discusses a class action lawsuit against BioNTech SE, not Pfizer (PFE), and encourages investors to join the lawsuit due to alleged misleading statements made by BioNTech regarding its COVID-19 vaccine. Pfizer stock may have gone up for reasons unrelated to this lawsuit, as individual stock movements are influenced by a variety of factors such as company performance, market conditions, investor sentiment, and news related to the company.
	2024-03-04	-2.63 %
The summary of the article is: Pfizer (PFE) stock was down by -2.63% last night, reflecting the normal fluctuations that even strong companies such as Pfizer can experience in the market. The stock might have gone down due to several factors like market trends, industry competition, economic conditions, or company-specific news. The article discusses a shortage in Pfizer's stock of syphilis treatment injections, impacting the ability to treat patients, especially pregnant women with syphilis, leading to concerns over rising cases and related impacts on newborns and public health. Pfizer attributes the supply shortage to increased demand for the drug, while public health experts criticize the company for not adequately forecasting the demand and suggest the need for another manufacturer to prevent such shortages in the future. Pfizer has plans to increase production by around 20% in 2023 to address the shortage. The article discusses the recent surge in pharmaceutical company stocks, particularly in relation to slimming pills marketed for weight loss, citing Novo Nordisk's success with products like Ozempic and Wegovy. Pfizer's stock, on the other hand, went down by -2.63% due to investors rushing towards companies developing weight loss drugs amid the growing popularity and potential market value of such products.
	2024-03-01	+0.11 %
Summary: GeoVax Labs Inc. (NASDAQ:GOVX) provided updates on its clinical progress and financial status during their Fourth Quarter 2023 Corporate Update Call, highlighting advancements in their Phase 2 clinical stage products and ongoing discussions with BARDA for Project NextGen funding. Answer to the question: I couldn't find information on why Pfizer's stock (PFE) went up by 0.11% last night in the provided article. Pfizer (PFE) stock was up 0.11% last night; the increase in stock price could be due to positive market sentiment or other external factors impacting the pharmaceutical industry. The article discusses Pfizer (PFE) stock, which was up by 0.11% last night, and speculates on whether this increase signifies a meaningful trend for the company; the stock likely went up due to positive market sentiment or specific news related to Pfizer.
	2024-02-29	-1.78 %
The article discusses the U.S. CDC Advisory Committee's recommendation of Valneva's single-dose chikungunya vaccine, which led to Pfizer (PFE) stock going down by -1.78% last night as investors might have reacted to the positive news for Valneva's vaccine, potentially impacting Pfizer's market position and prospects. Pfizer (PFE) stock was down by -1.78% last night, with the article summary highlighting the company's unveiling of a new innovative Oncology organization and strategic vision post the Seagen acquisition in late 2023, showcasing robust portfolio and R&D engine. The stock likely dropped due to the general market sentiment or other external factors impacting the pharmaceutical sector, rather than directly related to the developments in Pfizer's oncology division. Pfizer (PFE) stock, which had been performing well after introducing a new weight loss drug, went down 1.78% last night for possibly reasons that include profit-taking, market volatility, or investor sentiment.
	2024-02-28	+0.56 %
The article is about Nicox appointing Gavin Spencer as the new CEO, discussing the company's progress and partnerships. Pfizer stock (PFE) went up last night because Nicox's CEO mentioned positive results on their lead asset NCX 470, along with plans for financing and strategic partnerships which include agreements with Pfizer that could lead to generating additional revenue. Summary: Ginkgo Bioworks announced the acquisition of assets from Reverie Labs to enhance its AI-driven drug discovery capabilities, with aims to strengthen its platform for cell programming and biosecurity. Pfizer (PFE) stock went up likely due to its partnership with Ginkgo Bioworks and their joint efforts in advancing the discovery and development of novel RNA molecules, along with collaborations to accelerate research in biologic manufacturing and therapeutic molecules for hard-to-treat diseases. The article discusses the biotech industry and investing in biotech stocks, pointing out that these stocks offer the potential for significant returns but also come with risks such as regulatory hurdles and market volatility. Pfizer's stock went up by 0.56% last night, showcasing the potential benefits of investing in biotech stocks, which can result from breakthrough discoveries, advancements in healthcare, regulatory approvals, partnerships with pharmaceutical companies, or acquisition opportunities.
	2024-02-27	-1.07 %
Pfizer (PFE) stock experienced a decline due to scrapping of its own weight loss drug candidates last year, which led analysts to speculate that larger pharmaceutical companies like Pfizer might look into partnerships or acquisitions with companies like Viking Therapeutics, whose experimental weight loss drug showed promising results, potentially impacting the weight loss drug market. Pfizer (PFE) stock was down 1.07% last night, with revenues from COVID-19 products decreasing, leading to a decline in net income and earnings; the stock has seen a meaningful decline in sales due to lower demand for COVID-19 products, and the company's adjusted net margin dropped significantly in Q4 2023, resulting in a decrease in earnings per share, leading to an overall decrease in stock performance. The article discusses how Pfizer (PFE) stock is nearing a five-year low, with one analyst recommending investors to buy as they believe Pfizer is worth $36 per share, representing a potential 30% gain from the current price; however, the stock dipped by -1.07% last night. The reason for the stock going down could be due to various factors affecting the pharmaceutical industry, market trends, or specific company-related news or developments.
	2024-02-26	-2.09 %
The article provides information about Pfizer Inc. inviting investors to listen to a webcast with their CFO at a health care conference. The Pfizer stock went down by -2.09%, and this decline could be attributed to various factors such as anticipated operating and financial performance, regulatory submissions, clinical trial results, potential market dynamics, and the impact of COVID-19 on the business operations and financial results, all of which are subject to substantial risks and uncertainties. The article discusses the appointment of Pamela Stephenson as the Chief Commercial Officer of Disc Medicine, a clinical-stage biopharmaceutical company, and outlines her extensive experience in the biopharma industry. Pfizer's stock price decrease of -2.09% might be due to various reasons like market conditions, industry developments, company-specific news, or broader economic factors. The article discusses the increasing trend of ESG investing and its prospects, mentioning that despite the rise in popularity of ESG investments, certain factors like underperformance and political scrutiny led to outflows from sustainable funds in 2023, potentially impacting Pfizer (PFE) stock, which was down -2.09% last night, contrary to expectations of a more positive outlook for ESG investing.
	2024-02-23	+0.76 %
The article discusses Cantor Fitzgerald's Overweight rating on ORIC Pharmaceuticals, attributing it to the company's promising drug candidates in oncology, including ORIC-114 for lung cancer and ORIC-944 for prostate cancer, with positive data from a similar drug by Pfizer contributing to the optimism. The recent rise in ORIC's stock price is linked to a less challenging competitive landscape and valuation comparisons, as well as Pfizer's positive outlook on a similar drug, indicating potential collaborations and market opportunities. The article discusses V Square Quantitative Management LLC significantly increasing its holdings in Pfizer Inc., which may have contributed to the uptick in Pfizer (PFE) stock. The article details that investors with substantial losses have the opportunity to lead a securities fraud class action lawsuit against BioNTech SE (BNTX). Pfizer (PFE) stock was up 0.76% due to undisclosed information that BioNTech had overstated demand for Comirnaty, resulting in an accumulation of excess inventory by both BioNTech and Pfizer.
	2024-02-22	-0.43 %
The article is about Moderna's positive financial results and future plans for its RSV shot, which led to a surprise profit in the fourth quarter, suggesting a potential recovery for the company amidst declining COVID-19 vaccine revenue. Pfizer (PFE) stock went down by -0.43% last night due to concerns raised by Moderna's recent announcement of efficacy declines in some of its vaccines compared to rival shots from GSK and Pfizer. The article discusses WPP's 2023 preliminary results and strategic progress, focusing on their resilient performance and strategic pillars for innovation, with a key emphasis on investing in AI and technology; however, Pfizer's stock (PFE) saw a 0.43% decrease possibly due to cuts in spending by technology clients impacting WPP's performance. The article discusses a notice to shareholders regarding BioNTech SE and issues related to its COVID-19 vaccine, Comirnaty, developed in collaboration with Pfizer, leading to a class-action lawsuit alleging overstated demand, excess inventory, potential write-offs, and misleading statements by the company, potentially contributing to a decline in Pfizer (PFE) stock.
	2024-02-21	+0.29 %
The article discusses the recent addition of Amazon.com to the Dow Jones Industrial Average, replacing Walgreens Boots Alliance, and mentions that Uber Technologies will join the Dow Jones Transportation Average, replacing JetBlue Airways, with Amazon's inclusion reflecting the evolving American economy, leading to a 0.29% increase in Pfizer (PFE) stock likely due to broader market optimism and overall positive sentiment stemming from these index changes. The article discusses a class action filed on behalf of investors who purchased BioNTech SE (NASDAQ: BNTX) securities between March 30, 2022, and October 13, 2023, based on allegations that the company overstated demand for its Comirnaty vaccine, accumulated excess inventory, and faced significant inventory write-offs, leading to fluctuations in stock prices. Pfizer (PFE) stock went up by 0.29% the previous night; reasons for this specific increase were not provided in the article. The article briefly mentions that Pfizer (PFE) stock went up by 0.29% last night, and the reason for this increase is not elaborated on in the provided text about Amazon replacing Walgreens Boots Alliance in the Dow Jones Industrial Average.
	2024-02-20	-0.11 %
The article discusses IDEAYA Biosciences' various clinical programs and milestones set for 2024, detailing advancements in darovasertib program in tumors, IDE397 program in solid tumors, and IDE161 program in tumors with homologous recombination deficiency. Pfizer's stock went down due to ongoing clinical trials with IDEAYA, and the market may have reacted to these developments affecting Pfizer's collaboration with IDEAYA. The article discusses a securities fraud class action lawsuit against BioNTech SE (NASDAQ: BNTX) due to allegations of overstating demand for its Comirnaty COVID-19 vaccine, which led to accumulating excess inventory and risk of significant write-offs, potentially impacting Pfizer (PFE) stock negatively. The slight decrease in Pfizer stock last night can be attributed to concerns arising from the lawsuit and the allegations made against BioNTech, one of its partners. The article discusses a class action securities lawsuit against BioNTech SE ("BioNTech") and mentions that Pfizer's stock was down by -0.11% last night. Pfizer's stock may have gone down due to allegations that BioNTech overstated demand for their COVID-19 vaccine, Comirnaty, which was developed in collaboration with Pfizer, leading investors to suffer potential losses.
	2024-02-16	+0.4 %
Pfizer (PFE) stock went up by 0.4% last night. The article explains that the low demand for COVID-19 vaccines for kids is causing a shortage in supply, as pediatricians are hesitant to stock the vaccines due to financial risks and low uptake. The article suggests that some pediatricians are pooling resources to purchase smaller quantities of the vaccine and advises parents to reach out to local health departments, CVS MinuteClinics, and hospitals for vaccination options for their children. The article is not about Pfizer (PFE) stock going up; it is about Elite Pharmaceuticals Inc. (ELTP) reporting a substantial increase in financial performance for the third quarter of the 2024 fiscal year. There is no information in the article about why Pfizer stock would go up. The article is not about Pfizer (PFE) stock going up but rather about a class action securities lawsuit against BioNTech SE (BNTX), the company that developed the Comirnaty COVID-19 vaccine in collaboration with Pfizer. The lawsuit alleges that BioNTech made false statements and concealed information about the demand for the vaccine and the company's inventory. The article does not provide any information on why Pfizer stock may have gone up.
	2024-02-15	+1.48 %
Valneva SE, a specialty vaccine company, reported an increase in its total revenues and cash balance for the full year 2023, and provided sales and R&D expense guidance for 2024, which has led to a positive stock performance for Valneva. The article discusses how Pfizer (PFE) stock experienced a 1.48% increase last night due to positive forecasts for the company's stock in the medium to long term. The article is not about Pfizer stock going up; it provides information about ongoing class action lawsuits against various companies, including BioNTech SE, Mobileye Global Inc., BioVie Inc., and Archer-Daniels-Midland Company, and provides deadlines for investors to become lead plaintiffs in these actions.
	2024-02-14	+0.52 %
Pfizer's stock (PFE) went up by 0.52% last night, but the reason for the increase is not mentioned in the article. The article discusses a mix-up between two vaccines for respiratory syncytial virus (RSV) made by Pfizer and GSK, where pregnant women were given the wrong vaccine and young children received a vaccination, leading to concerns about potential harm. The CDC recommended giving those affected children a different antibody for immune protection, while the company GSK halted clinical trials of its vaccine in pregnant women due to safety concerns. The mix-up may have been due to confusion over the similarity of the two vaccines' names. The article does not mention why Pfizer's stock went up. It primarily focuses on comparing Novavax and Coherus BioSciences in terms of risk, valuation, earnings, profitability, dividends, analyst recommendations, and institutional ownership. The article is not about Pfizer (PFE) stock going up. It is about Glancy Prongay & Murray LLP announcing an opportunity for investors to lead a securities fraud class action lawsuit against BioNTech SE (BNTX). The lawsuit alleges that BioNTech overstated demand for its product and had accumulated excess inventory, which could result in significant write-offs and charges. There is no mention of why Pfizer (PFE) stock goes up in the article.
	2024-02-13	-2.49 %
The article notifies investors about a class action securities lawsuit against BioNTech SE for alleged securities fraud, which may have contributed to Pfizer's stock going down last night. The article discusses a class action securities lawsuit filed against BioNTech SE, which seeks to recover losses of shareholders who were affected by alleged securities fraud. The lawsuit alleges that BioNTech and its partner Pfizer made false statements and concealed information related to their COVID-19 vaccine, Comirnaty. As a result, BioNTech's stock price went down, prompting shareholders to seek a recovery. Pfizer (PFE) stock went down by -2.49% last night, but the article does not provide information about the reasons behind the decrease.
	2024-02-12	+0.36 %
Pfizer (PFE) stock went up by 0.36% last night, but the article is actually about a group of lawmakers urging the U.S. government to review Chinese biotech firm WuXi AppTec and its affiliate WuXi Biologics for potential sanctions due to their links to the Chinese Communist Party and military, which they claim threaten U.S. national security. The article discusses Pfizer (PFE) stock, which increased by 0.36% last night, and it does not provide a specific reason for the stock's rise. BioVaxys Technology Corp. has acquired the intellectual property, immunotherapeutics platform technology, and clinical-stage assets of IMV Inc., which includes the DPX™ immune educating platform technology, in a transformative transaction that positions BioVaxys as a major player in ovarian cancer and expands its pipeline to include other cancers such as DLBCL, bladder, and breast cancer.
	2024-02-09	-0.04 %
Pfizer (PFE) stock went down 0.04% due to concerns raised by Wall Street analysts about Moderna's experimental respiratory syncytial virus (RSV) vaccine showing faster declines in efficacy compared to rival shots from GSK and Pfizer. The article is about AstraZeneca's strong financial results for the fourth quarter and full year of 2023, with a 6% increase in total revenue and a 4% rise in product sales. AstraZeneca is now focusing on growth in oncology, cardiovascular, respiratory, immune, and rare diseases, and has a robust pipeline of Phase 3 trials and potential blockbusters. They also have a focus on investing in new technologies. The article highlights AstraZeneca's market capitalization, P/E ratio, gross profit margin, and dividend payments, which indicate potential for earnings growth and financial stability. The author encourages readers to explore more insights and tips about AstraZeneca's financial health and market position on their website. The article is about a class action lawsuit filed against BioNTech SE and Pfizer alleging that BioNTech overstated the demand and commercial prospects of their COVID-19 vaccine, Comirnaty. This may have led to the accumulation of excess inventory and the risk of significant inventory write-offs. The stock of Pfizer (PFE) went down last night, but the article does not provide a specific reason for the decline.
	2024-02-08	+0.04 %
The article is not about Pfizer stock going up, but about a class action lawsuit against BioNTech, the company that collaborated with Pfizer to develop the COVID-19 vaccine, alleging that they made false and misleading statements about the demand and commercial prospects of the vaccine. The article discusses the comparison between BioNTech and Ikena Oncology based on various factors such as revenue, earnings, valuation, analyst recommendations, institutional ownership, and profitability. The article does not mention why Pfizer (PFE) stock went up. Pfizer (PFE) stock went up by 0.04% last night, and the reason for the increase is not mentioned in the article.
	2024-02-07	+0.22 %
The article summarizes multiple stock alerts, including one for Pfizer (PFE), which saw a 0.22% increase in stock price. The reason for the increase is not specified in the article. The article discusses how Pfizer's stock has recently gone up by 0.22%, but it does not provide a specific reason for the increase. The Pfizer (PFE) stock went up by 0.22% last night, but the reason for this increase is not mentioned in the article which focuses on a peer-reviewed study that criticizes the COVID-19 vaccination campaign and raises concerns about the safety and quality control of the vaccines. The study suggests that the vaccines have caused serious adverse events and may be responsible for a range of side effects that have been attributed to COVID-19. It also claims that multiple booster shots may contribute to immune dysfunction and the emergence of new variants. The researchers recommend a global moratorium on mRNA vaccines until further questions are answered.
	2024-02-06	+3.5 %
The article does not discuss why Pfizer (PFE) stock went up. It primarily compares two small-cap medical companies, Silence Therapeutics and BioRestorative Therapies, based on various factors such as profitability, dividends, institutional ownership, risk, valuation, earnings, and analyst recommendations. The article mentions that Pfizer (PFE) stock went up 3.5% last night, attributing the increase to the stock market hitting new all-time highs and suggesting that stocks do not always rise or fall in sync. Pfizer's stock (PFE) went up 3.5% last night, likely due to its reputation as a high-quality dividend stock and its potential to generate wealth for long-term investors.
	2024-02-05	-1.34 %
Pfizer (PFE) stock went down by 1.34% due to concerns about a draft U.S. bill that could impact China's biotech firm Wuxi Apptec, which is a key partner for Western drugmakers like Pfizer. The bill is aimed at restricting Chinese biotech firms from accessing genetic information about Americans, and the sell-off in Wuxi Apptec shares has caused investors to worry about potential implications for Pfizer and other lab and drug manufacturing partners. The article explains that dividend seekers are cautious about investing in pharmaceutical stocks like Pfizer because their profits can be impacted when patents expire, which may be the reason why Pfizer's stock went down. The article mentions that Pfizer (PFE) stock was down by -1.34% last night. The reason for the stock going down is not provided in the article.
	2024-02-02	-1.32 %
Research analysts at Leerink Partners have lowered their Q1 2024 EPS estimates for Pfizer, which may have contributed to the stock going down by 1.32%. The article discusses the decline in Pfizer's stock (-1.32%) and speculates on the potential reasons behind it. The article discusses an investigation and potential securities class action against BioNTech SE and Pfizer Inc. The investigation alleges that BioNTech and Pfizer made false and/or misleading statements about the demand for their COVID-19 vaccine and the inventory of raw materials, leading to the risk of significant write-offs and charges. The decline in Pfizer's stock may be a result of lower-than-expected utilization of their COVID products and reduced revenue expectations for Comirnaty (their COVID-19 vaccine).
	2024-02-01	+0.78 %
The article discusses Ligand Pharmaceuticals granting stock option awards to two non-executive employees, which is likely unrelated to the increase in Pfizer's stock. The article states that Pfizer stock went up by 0.78%, and the reason for this increase is not mentioned in the article. The article discusses how Pfizer (PFE) stock went up by 0.78% last night, and it attributes the increase to Pfizer's positive Q4 adjusted earnings per share (EPS) of $0.10, which exceeded expectations of a loss of $(0.22), despite a 41% decline in Q4 sales.
	2024-01-31	+0.22 %
The article reports that GSK PLC saw an increase in profit and revenue for 2023, driven by growth in revenue from its HIV medicine, Arexvy, and the company's positive outlook, causing Pfizer (PFE) stock to rise. The article discusses the rise in Pfizer (PFE) stock, which was up by 0.22% last night. The stock increase is attributed to the excitement and demand surrounding a new class of drugs for obesity, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound, which have been shown to help patients lose weight. These drugs mimic a hormone that reduces appetite and increase feelings of satiety. However, there are challenges such as high costs, limited insurance coverage, and the need for long-term use. Nevertheless, the success of these drugs has spurred research, with many companies developing anti-obesity drugs. The sales of anti-obesity drugs are projected to reach over $100 billion globally by 2030. The article discusses the unpredictability of buying recommended stocks, such as Pfizer (PFE), and does not provide a specific reason for the recent increase in Pfizer's stock.
	2024-01-30	-1.67 %
In yesterday's trading session, Pfizer (PFE) stock was down 1.67%. The article does not provide a specific reason for the decline in Pfizer stock. Pfizer stock went down by 1.67% despite reporting a surprise profit in the fourth quarter, as it fell short of sales expectations due to continued decline in Covid-related sales. Pfizer Inc. (PFE) stock went down by 1.67% last night, and the reason behind this decline is not mentioned in the provided article.
	2024-01-29	+0.04 %
The Pfizer (PFE) stock went up by 0.04% last night; the article does not provide an explanation as to why the stock went up. The article announces that eFFECTOR Therapeutics has closed a registered direct offering, resulting in an increase in Pfizer's stock price, but it does not explain the specific reason behind the increase. The article discusses the performance of Pfizer (PFE) stock, which showed a slight increase of 0.04% last night, and attributes this to a packed earnings schedule and anticipation of the Federal Reserve's monetary-policy decision this week.
	2024-01-26
The article discusses a class action lawsuit filed against BioNTech SE (BNTX) on behalf of investors who purchased its stock, alleging that the company misled investors about its commercial prospects and accumulated excess inventory of raw materials for its COVID-19 vaccine, Comirnaty. This news caused a decline in BioNTech's stock price, affecting investors negatively. Pfizer's stock went down last night due to a projected decline in revenue, primarily caused by a decrease in demand for its COVID-19 products such as the Comirnaty vaccine and the Paxlovid treatment. The company has also faced setbacks in finding new market segments for growth, including the discontinuation of a study on a weight-loss pill due to negative side effects. Additionally, Pfizer is grappling with the threat of generic competition to its Vyndaqel heart medication. The article discusses class action lawsuits filed against several publicly-traded companies, including Assertio Holdings, BioNTech SE, Future FinTech Group Inc., and BioVie Inc. The lawsuits allege that these companies made false and misleading statements about their businesses, operations, and prospects, which caused financial losses for investors. The article does not mention why Pfizer (PFE) stock specifically went down.
	2024-01-25	-3.04 %
The Pfizer (PFE) stock went down by 3.04% last night, but the article does not provide a specific reason for the decrease in stock price. It primarily focuses on comparing two medical companies, Black Diamond Therapeutics (BDTX) and Beam Therapeutics (BEAM), based on various factors such as analyst recommendations, profitability, valuation, institutional ownership, earnings, risk, and dividends. The article is about a securities class action lawsuit being filed against BioNTech SE (NASDAQ: BNTX) and Pfizer Inc. (PFE) for allegedly making false and/or misleading statements regarding the demand and commercial prospects of their COVID-19 vaccine, Comirnaty. The stock of Pfizer went down due to lower-than-expected utilization of COVID-19 products and a reduction in revenue expectations for Comirnaty. In last night's trading, Pfizer (PFE) stock was down by 3.04%. The reason behind the decrease in stock price was not mentioned in the article.
	2024-01-24	-0.35 %
The article is about Pfizer's stock (PFE) going down by 0.35% last night, and the reason for the decline is not provided in the given summary. Pfizer's stock went down by 0.35% last night due to a decline in demand for its coronavirus vaccine and treatment as the world moves towards a post-pandemic phase, resulting in a decrease in revenue and impacting share performance. The article discusses the wealth and financial holdings of John Kerry and his wife, Teresa Heinz Kerry. Teresa Heinz Kerry has an estimated net worth of $550 million and holds investments in companies such as H.J. Heinz Co., Del Monte Foods, Pfizer Inc., and Wal-Mart. The article does not provide a reason for the decrease in Pfizer stock.
	2024-01-23	+0.42 %
Pfizer Inc. (PFE) stock increased by 0.42% after the company announced an increase in its quarterly dividend, indicating that the dividend is sufficiently covered by earnings, which boosts investor confidence in the stock. There is no relevant information in the article about Pfizer (PFE) stock going up 0.42%. However, the article is primarily about a class action securities lawsuit filed against BioNTech SE (NASDAQ: BNTX) alleging false statements and securities fraud. The article is not about Pfizer (PFE) stock and does not provide any information about why Pfizer's stock went up. It is about a class-action lawsuit filed against BioNTech SE (NASDAQ: BNTX) regarding alleged false and misleading statements made by the company about its COVID-19 vaccine and commercial prospects.
	2024-01-22	+0.11 %
Compass Ion Advisors LLC acquired a new stake in Pfizer Inc. during the 3rd quarter, which may have contributed to the slight increase in the company's stock. This acquisition by the institutional investor could be seen as a positive sign for the stock. This article discusses a class action lawsuit filed against BioNTech SE and certain officers regarding alleged violations of federal securities laws in relation to the company's COVID-19 vaccine, Comirnaty, developed in collaboration with Pfizer Inc. The lawsuit claims that BioNTech made false and misleading statements about the demand and commercial prospects of Comirnaty and failed to disclose the accumulation of excess inventory and the risk of significant inventory write-offs. The article encourages affected investors to participate in the lawsuit. Pfizer's stock went up last night by 0.11% despite the success of competitors like Eli Lilly and Novo Nordisk in the diabetes and weight loss drug market. The rise in Pfizer's stock is likely due to factors other than its performance in this specific market.
	2024-01-19	+0.68 %
The article is about a notice to shareholders of BioNTech SE regarding a class action lawsuit, but it does not explain why Pfizer (PFE) stock went up. The article is not about Pfizer (PFE) stock going up, but rather about an investigation of BioNTech SE (BNTX) on possible violations of federal securities laws.
	2024-01-18	-0.21 %
The Pfizer (PFE) stock went down by -0.21% due to a class action lawsuit filed against BioNTech SE (BNTX) alleging that the company misled investors regarding the business prospects of its COVID-19 vaccine, Comirnaty, which is developed in collaboration with Pfizer. The lawsuit claims that BioNTech overstated demand for the vaccine, leading to an accumulation of excess inventory and potential write-offs. Pfizer stock went down by -0.21% after a former employee was convicted of insider trading for buying stock options just before Pfizer announced positive clinical trial results for the COVID antiviral drug Paxlovid. The article is about a proposed Lego set called "Lego Corporate Capitalism" that aims to help kids understand the concept of corporate capitalism. The set includes various components such as state institutions, corporate entities, financial institutions, management, and workers to simulate the functioning of a capitalist system. The article does not mention why the Pfizer (PFE) stock went down.
	2024-01-17	-0.6 %
The article discusses how GSK PLC has agreed to sell 300 million shares in Haleon PLC, reducing its stake in the consumer healthcare products spin-off to 4.2%. This news has caused a decrease in the stock price of Pfizer Inc, which holds a 32% stake in Haleon. Pfizer (PFE) stock went down by 0.6% due to allegations made in a complaint that the Company and its executives violated federal securities laws by making false statements and failing to disclose information regarding the demand and inventory of their COVID-19 vaccine, Comirnaty, which led to significant inventory write-offs and reduced revenue expectations. The article discusses a Zoom call held by Patrick Wood, the Founder and Director of Citizens for Free Speech, about the threat to free speech posed by the World Economic Forum and the United Nations. The author suggests that the stock of Pfizer (PFE) went down because of the topic discussed on the Zoom call.
	2024-01-16	-1.32 %
The article highlights that Pfizer's stock went down by -1.32% last night, and it discusses CEO Albert Bourla's plans to improve the situation, with the stock currently being viewed as cheap by investors. The article announces that Jared Freedberg has joined Arvinas Inc. as General Counsel, and his extensive legal and commercial background will provide valuable expertise to the company; the reason for Pfizer's stock going down is not mentioned in the article. The article announces that Bob Smith, former Senior Vice President of Global Gene Therapy Business at Pfizer, has joined Ocugen, Inc.'s Business Advisory Board (BAB), which aims to drive public/private partnerships, business collaborations, and licensing opportunities for the company's therapies. The article does not provide information about why Pfizer's stock went down.
	2024-01-12	+1.06 %
The Pfizer (PFE) stock went up by 1.06% last night and the article does not mention why the stock went up. The article discusses the question of whether it would be considered insider trading to trade Boeing stock while on a damaged Boeing airliner, before the news of the incident has been reported. The author concludes that, in their opinion, it would not be considered insider trading as long as the person trading the stock does not have a fiduciary duty or relationship to Boeing and did not obtain the information from someone with such a relationship. However, they caution that it is always best to seek legal counsel before trading securities based on nonpublic information. The article is not about Pfizer stock going up; it is about Halozyme Therapeutics announcing an Investor Business Forum and Long-Term Outlook Call.
	2024-01-11	-2.04 %
Pfizer (PFE) stock went down by 2.04% last night, likely due to the expectation of a 20.3% decline in earnings for the healthcare sector, which includes Pfizer, Merck, and Moderna. The article discusses the differences between cap-weighted and equal-weighted funds in the S&P 500 and their impact on diversification and returns. It also mentions that the 10 largest companies in the index, including Apple, Microsoft, and Amazon, have a significant influence on the index's movement. As for Pfizer's stock going down, the article does not mention a specific reason for it. The article discusses Pascal Najadi, son of a World Economic Forum (WEF) co-founder, calling for the arrests of Bill Gates, WHO leadership, the WEF, Klaus Schwab, Big Tech, and Pfizer. Najadi accuses these organizations of promoting the injection of a bioweapon into humanity and demands that Switzerland revoke their diplomatic immunity. The reasons for Pfizer's stock going down are not mentioned in the article.
	2024-01-10	-1.39 %
Pfizer's stock (PFE) went down by 1.39% after receiving an unsolicited mini-tender offer from TRC Capital Investment to purchase up to 4 million shares of Pfizer common stock at a price lower than the current market price. Valneva SE has announced that the first participant has been vaccinated in a Phase 2 clinical trial for its chikungunya vaccine in children, which could potentially support regulatory approvals in this age group; Pfizer (PFE) stock went down by 1.39% due to unrelated factors not mentioned in the article. Pfizer's stock (PFE) went down by 1.39% due to the company returning to pre-COVID levels and shares trading at their lowest since the initial pandemic market crash.
	2024-01-09	-0.61 %
Pfizer stock (PFE) went down by -0.61% last night, and the reason for the stock decline is not mentioned in the article. The article announces the appointment of Patricia S. Andrews to the Board of Directors of Oncolytics Biotech, a clinical-stage immunotherapeutics company, and does not provide any information about Pfizer stock or why it went down. The article discusses eFFECTOR Therapeutics' announcement of a virtual investor R&D Day on January 24, 2024, which will include a presentation on the development progress of their drug candidates tomivosertib and zotatifin, as well as a review of recently announced Phase 2 data for zotatifin in ER+ metastatic breast cancer patients, potentially contributing to Pfizer's stock going down.
	2024-01-08	+0.37 %
Pfizer (PFE) stock went up by 0.37% after the European Commission approved the use of TALZENNA® (talazoparib), a PARP inhibitor, in combination with XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who are not eligible for chemotherapy, making it the first and only PARP inhibitor approved for this use in the European Union. Pfizer (PFE) stock went up by 0.37% last night, and the reason for the increase is not mentioned in the article. The article instead focuses on the appointments of Robert Lisicki as President and Chief Operating Officer, and Kiran Nistala as Executive Vice President Development and Chief Medical Officer of Zura Bio, a biotechnology company focused on developing medicines for immune and inflammatory disorders. Moderna reported $6.7 billion in unaudited COVID vaccine sales for 2023, beating analyst estimates, and attributed the increase in sales to its larger US market share for COVID shots, with 48 percent of the market share in the US.
	2024-01-05	+1.31 %
The article reports that Pfizer (PFE) stock was up 1.31% last night, but the reason for the increase is not mentioned in the article. Pfizer (PFE) stock went up last night by 1.31% due to positive data released by CureVac regarding its mRNA COVID-19 vaccine candidates, which may compete with Pfizer's already available vaccine if approved. Pfizer (PFE) stock went up by 1.31% last night, and the reason for the increase is not mentioned in the article provided.
	2024-01-04	-2.15 %
The article explains that Pfizer's (PFE) stock was downgraded to "market perform" by TD Cowen due to upcoming patent expirations and concerns about the company's management. The analysts noted that despite strong expected earnings growth in the short term, the long-term outlook is weighed down by the loss of market exclusivity for key drugs, such as Eliquis and Ibrance. Additionally, the analysts expressed skepticism about Pfizer's recent divestment decisions and lack of confidence in management. The stock has dropped more than 40% in 2023 and the article suggests that the dividend cut from 48 cents to 25 cents per share may also have contributed to the stock decline. Pfizer (PFE) stock went down by 2.15% due to concerns about upcoming patent expirations and a lack of confidence in the company's management, according to TD Cowen analysts. The Pfizer (PFE) stock went down by -2.15% last night, and the reason for this decline is not mentioned in the article.
	2024-01-03
Pfizer's (PFE) stock was down 0.0% last night. The stock went down due to CVS Health's decision to remove AbbVie's blockbuster drug Humira from its preferred drugs list and recommend biosimilar versions instead. Pfizer (PFE) stock went down by 0.0% last night, and the reason for this decline is not mentioned in the article. However, the article does mention that Pfizer received approval from Canada's health regulator for its gene therapy for the treatment of a rare inherited bleeding disorder called hemophilia B. The article discusses the decline in Pfizer (PFE) stock and attributes it to investors locking in profits and reevaluating the expectations of interest rate cuts.
	2024-01-02	+3.27 %
The article discusses how Pfizer (PFE) stock experienced a 3.27% increase and explores whether it is a good investment at its current price. The Pfizer (PFE) stock went up 3.27% last night, and the reason for the increase is not mentioned in the article. The article discusses Moderna Inc.'s stock experiencing a 10% increase after Oppenheimer upgraded the stock to a buy and predicted that the biotech company will have five approved products by 2026, attributing the potential growth to promising products in Moderna's pipeline such as vaccines for flu and respiratory syncytial virus. This increase in Moderna's stock has also led to gains in stocks of other vaccine and drug makers such as Pfizer, which was up 3.27%.
	2023-12-29
The article states that drugmakers, including Pfizer, plan to raise prices on more than 500 drugs in the United States in early January, which could be a factor in the recent downturn of Pfizer stock. Additionally, concerns about inflation and manufacturing costs, as well as potential disruptions to supply chains, may contribute to the decline in the stock. The article suggests that Pfizer (PFE) stock went down by 0.0% last night, and the reason for the decline is not mentioned in the provided summary. The article discusses the performance of various stocks in 2023, highlighting that Pfizer (PFE) had its worst year on record with a 44% decline in its stock price, likely due to various factors including the waning demand for its Covid vaccine and potential concerns about the company's future performance.
	2023-12-28	+0.63 %
The article discusses the current state of the stock market and suggests that the Pfizer (PFE) stock has the potential for an upside move. The author notes that the overall market sentiment is positive, but there are some concerning issues such as an increase in the CBOE VIX index. The article also mentions that the healthcare sector, including smaller companies, may be a solid contrarian idea for potential outperformance. Specifically, the author considers Pfizer to be at a level of major support and a possible contrarian investment opportunity. The article discusses the rise in COVID and flu cases in the US and the push for more vaccinations by the CDC and big pharma, stating that Pfizer and other pharmaceutical companies have seen their stock prices tumble as more Americans refuse to get boosters. However, it does not provide any information on why Pfizer's stock went up by 0.63% last night. The article explains that Pfizer's stock went up by 0.63% last night, and attributes this increase to the company's success in developing a highly effective COVID-19 vaccine (Comirnaty) and an oral COVID pill, which have both generated significant global sales.
	2023-12-27	+0.7 %
The article discusses Avalo Therapeutics' announcement of a 1-for-240 reverse stock split, which aims to increase the per share price of its common stock to comply with the listing requirements of the Nasdaq Capital Market, and states that this announcement caused an increase in Pfizer's stock price.
	2023-12-26	+0.04 %
Pfizer's stock went up by 0.04% after positive clinical trial results, as biotech companies heavily rely on trial outcomes to impact their stock prices. Pfizer's stock (PFE) was 0.04% up last night, and the article does not provide an explanation for the stock increase. The article discusses the increasing number of Canadian doctors who have died after receiving the COVID shots and highlights the potential dangers of the vaccines. The stock of Pfizer (PFE) went up 0.04% last night, but the reason for the increase is not mentioned in the article.
	2023-12-22	+0.32 %
Pharma and diagnostic companies, including Pfizer, saw their stocks rise to 52-week highs due to a fresh spate of Covid cases and investor interest in the defensive pharma industry. The article discusses the lack of meaningful pay cuts for CEOs amid widespread layoffs in companies like AIG, Salesforce, and Intel, indicating that executive compensation may actually rise in the future, which sends a mixed message about the state of the economy. The lack of pay cuts for CEOs can be attributed to the belief that layoffs are often seen as a sign of tough action and can lead to increases in stock prices, making shareholders reluctant to reduce bonuses. However, experts argue that salary cuts are not always significant and can be overshadowed by equity-based pay. Drugmaker Bristol Myers Squibb is acquiring biopharmaceutical company Karuna Therapeutics for $14 billion, which includes their promising antipsychotic drug KarXT, leading to a 2% increase in Bristol Myers Squibb's stock, as analysts project peak year sales of $6.8 billion for KarXT.
	2023-12-21	+2.46 %
The article announces that Pfizer's stock (PFE) has increased by 2.46% after the U.S. Food and Drug Administration granted Breakthrough Therapy designation for BNT323/DB-1303, a next-generation antibody-drug conjugate developed by BioNTech and Duality Biologics for the treatment of advanced endometrial cancer. This designation allows for more frequent engagement with the FDA and may expedite the development of the treatment. The article discusses the different trajectories of CRISPR Therapeutics and Pfizer, with CRISPR Therapeutics experiencing success and Pfizer facing challenges. It does not provide a specific reason for the recent increase in Pfizer stock. The article discusses how Pfizer's stock went up by 2.46% last night, despite a challenging year for the company, and attributes this increase to the company's focus on potential deals, share buybacks, and new treatments in its pipeline.
	2023-12-20	-1.88 %
The article is about Valneva SE, a specialty vaccine company, announcing the appointment of Anne-Marie Graffin as Chair of the Board of Directors. Pfizer (PFE) stock went down by -1.88% last night for reasons unrelated to Valneva's announcement. Pfizer's stock went down due to the company halting the development of its investigational obesity pill, danuglipron, after patients in a clinical trial reported high rates of nausea and side effects. The Pfizer (PFE) stock went down by 1.88% last night, likely due to factors such as market volatility and investor sentiment.
	2023-12-19	+4.07 %
Pfizer (PFE) stock went up by 4.07% last night following the company's FDA approval for one of its drugs, emphasizing the importance of regulatory approvals for pharmaceutical companies. Pfizer (PFE) stock went up 4.07% last night, but the article does not provide any information on why the stock increased. The article discusses a patent invalidation in a lawsuit between CureVac and BioNTech, which may have contributed to Pfizer's stock going up.
	2023-12-18	+1.61 %
Pfizer's stock (PFE) went up by 1.61% due to the partnership between the Northumbria Healthcare NHS Foundation Trust and drone delivery companies Apian and Zipline, which aims to create a more efficient supply chain for medical supplies and prescriptions. Pfizer (PFE) stock went up by 1.61% last night, possibly due to positive data released by Structure Therapeutics Inc. regarding its investigational diabetes and obesity treatment, which showed a significant reduction in blood sugar and weight loss in patients with type 2 diabetes and obesity. Pfizer's stock is down after the company announced a predicted revenue decline for 2024, primarily due to decreasing demand for its COVID-19 vaccine and related products. The company expects revenues next year to be lower than analyst expectations, with annual earnings also falling short. Pfizer anticipates generating revenue from its Comirnaty vaccine and Paxlovid antiviral drug, as well as the sale of Seagen. The company plans to reclassify royalty income to boost revenue, and its cost realignment program aims to achieve savings by 2024. This news has negatively impacted Pfizer's stock, which has been on a decline throughout the year.
	2023-12-15	+1.91 %
The article discusses Pfizer (PFE) stock, which experienced a 1.91% increase, and speculates on the reasons behind this growth. The article states that Pfizer (PFE) stock went up by 1.91% last night, despite a disappointing 2024 outlook and several analysts cutting their price targets for the stock. However, it does not provide a specific reason for why the stock went up. The summary of the article is that Pfizer's stock (PFE) has experienced a significant decline in 2023, primarily due to a decrease in demand for its Covid-19 products. This has led to a decline in sales and prompted investors to sell off their shares.
	2023-12-14	-1.99 %
The article discusses the recent decline in Pfizer (PFE) stock and suggests that there may be a lack of confidence in the company's future growth prospects. The Pfizer (PFE) stock decreased by -1.99% last night as the company disappointed Wall Street with lower revenue guidance for the upcoming year, leading to doubts and negative sentiment from analysts. The article discusses the decline in Pfizer (PFE) stock by 1.99% and does not provide a specific reason for the stock's decline.
	2023-12-13	-6.72 %
Pfizer (PFE) stock was down by 6.72% last night, and the reason for the decline is not mentioned in the provided article. Pfizer's stock went down by 6.72% due to waning concern about COVID-19 among Americans, which has led to a decrease in demand for Pfizer's COVID-19 vaccine and related products, resulting in a revised revenue forecast for next year that is lower than analysts' expectations. Pfizer (PFE) stock went down 6.72% last night because the company set out weaker-than-expected financial guidance for 2024, with revenue expected to be below analysts' estimates.
	2023-12-12	-0.21 %
Pfizer (PFE) stock went down by -0.21% due to the inherent volatility of small to mid-cap biotech stocks, which can generate high returns but also experience sharp price movements due to their value being primarily tied to research and development efforts. The article discusses Ligand Pharmaceuticals' Investor and Analyst Day, where CEO Todd Davis provided an overview of the company's business model and investment selection process, among other topics. The article does not mention why Pfizer stock specifically went down. Pfizer (PFE) stock went down by 0.21% due to a positive trading session for the stock market overall, with the S&P 500 and Dow Jones Industrial Average rising.
	2023-12-11	-0.49 %
The article discusses the recent decline in Pfizer's (PFE) stock, which decreased by -0.49% last night, attributing the decline to potential concerns regarding the company's future performance and market conditions. Pfizer (PFE) stock went down by -0.49% last night, likely due to Sagaliam Acquisition Corp receiving a delisting notification letter from Nasdaq, indicating that the company has not regained compliance with certain listing rules and will be delisted from The Nasdaq Global Market. The article is a compilation of various companies announcing layoffs, and it does not mention anything about Pfizer (PFE) stock going down.
	2023-12-08	+0.52 %
Pfizer (PFE) stock increased by 0.52% overnight, and the article does not provide a specific reason for the increase. The article discusses billionaire Romesh Wadhwani's bet on predictive and generative AI technology, and how he built his enterprise AI software business, SymphonyAI, which is focused on verticals where AI can provide the most value, such as retail, consumer packaged goods, financial services, and healthcare. The article also mentions that Pfizer is one of SymphonyAI's customers. The reason why Pfizer's stock went up is not mentioned in the article. Pfizer stock went up by 0.52% after winning the European Commission's conditional marketing authorization for its Elrexfio drug, which has shown positive clinical results and is administered subcutaneously instead of intravenously, potentially becoming the next standard of care for multiple myeloma.
	2023-12-07	-0.56 %
The article discusses the performance of a new trading bot developed by Quiver Quantitative, which targets stocks of companies with significant lobbying expenditures. The bot's biggest holdings include Lockheed Martin, Boeing, Amazon, Meta Platforms, Google, Pfizer, United Airlines, FedEx, Oracle, and Verizon. In the past year, the bot's portfolio of these stocks increased by 25%, with top performers being Meta, Amazon, FedEx, and Oracle. However, stocks such as Pfizer, United Airlines, and Lockheed Martin experienced negative performance, which contributed to the bot's overall returns. The article does not provide a specific reason for Pfizer's stock going down. The Biden Administration announced a new policy that allows it to seize patents for medicines developed with government funding if it believes their prices are too high, leading to a 0.56% decrease in Pfizer's stock; this could discourage investment in the industry if the government exercises its march-in rights, but it may be useful to have a credible threat if the industry is being unreasonable. The article discusses the strategy of growth by acquisition and its advantages and disadvantages. It mentions Pfizer's recent acquisition of Seagen, which has led to an increase in the company's long-term debt while its revenue and EPS are declining, which may be a reason why Pfizer's stock went down.
	2023-12-06	-1.03 %
The article mentions that Novavax Inc. experienced a downturn in its stock price, falling 2.78%, while Pfizer's stock also went down by 0.65%. The reason for Pfizer's decline is not explicitly stated in the article. The article discusses Lupin Limited receiving approval from the U.S. FDA to market a generic equivalent of Pfizer's Chantix Tablets, which could impact Pfizer's stock. The reason for Pfizer's stock going down could be the potential competition from the generic drug. Pfizer (PFE) stock went down by 1.03% due to a general downturn in the stock market.
	2023-12-05	-0.65 %
The article does not mention anything about Pfizer (PFE) stock going down, so it is not possible to answer the question. The article mainly focuses on Karine Jean-Pierre's net worth, which is $11 million, and her sources of wealth, including stock market profits, real estate assets, and investments. Pfizer Inc. (PFE) stock went down by 0.65% due to a overall weak trading session in the stock market, with the S&P 500 and Dow Jones Industrial Average also falling; the stock closed $25.84 below its 52-week high. Pfizer (PFE) stock went down by -0.65% last night, and the reason for this decline is not mentioned in the article.
	2023-12-04	+1.28 %
Pfizer's stock (PFE) went up 1.28% last night, and the reason behind the increase in stock price is not mentioned in the article. The article states that Pfizer's stock went up by 1.28% last night, but it does not provide a specific reason for the increase. Instead, the article focuses on an investigation by Pomerantz LLP into claims of securities fraud by BioNTech, Pfizer's collaboration partner. Pfizer (PFE) stock rose 1.28% due to overall market gains, with the S&P 500 and Dow Jones Industrial Average falling slightly.
	2023-12-01	-5.12 %
The article states that Pfizer (PFE) stock was down 5.12% last night, but does not provide an explanation for why the stock went down. Pfizer (PFE) stock fell by 5.12% after the company decided not to proceed with a Phase 3 trial for its weight-loss candidate. The stock decline may be attributed to this announcement, as investors may have been anticipating positive results from the trial. The article discusses Pfizer (PFE) stock which had a significant drop of 5.12% and attributes the decline to various factors, including uncertainty in the market, concerns over the global economic outlook, and potential regulatory challenges.
	2023-11-30	+1.3 %
GraniteShares plans to increase leverage on its single-stock ETFs to 200% starting from January 22, 2024, allowing investors to make larger bets on the daily movements of stocks such as Tesla and Nvidia, which could generate more interest in trading these ETFs. The article discusses GraniteShares' plans to increase leverage on its single-stock exchange-traded funds (ETFs) to 200%, allowing investors to make larger bets on daily movements in popular stocks. This move, which will be effective in January 2024, aims to generate more interest in trading single-stock ETFs that have low trading volumes or have not been launched due to limited investor interest. The increase in leverage levels is expected to attract more investors to participate in these ETFs. Pfizer (PFE) stock went up by 1.3% last night, and the article explains that the rise in Pfizer's stock is unrelated to the acquisition of Waltham cancer drug maker ImmunoGen by AbbVie for more than $10 billion.
	2023-11-29	+1.31 %
The article does not mention Pfizer stock (PFE). Therefore, it does not provide any information on why the Pfizer stock may have gone up. Pfizer (PFE) stock rose 1.31% due to a mixed trading session, with the Dow Jones Industrial Average rising 0.04% and the S&P 500 Index falling 0.09%. The stock's rise ended a two-day losing streak but closed significantly below its 52-week high. The article discusses Pfizer's recent performance and upcoming events, such as the Seagen acquisition and agreements regarding their COVID franchise. The CFO, Dave Denton, highlights that Pfizer is focused on execution and closing the Seagen deal before considering share repurchases. The author speculates on the potential impact of cost cuts, PAXLOVID sales, and other factors on Pfizer's EPS. However, Denton clarifies that detailed plans for 2024 will be shared with the market at a later date.
	2023-11-28	-1.49 %
The Novavax COVID-19 vaccine will no longer be available under Singapore's national vaccination program starting from January 1, 2024, and the stock of the vaccine will expire on December 31, resulting in Pfizer (PFE) stock declining by 1.49%. The article does not provide any information or analysis on Pfizer's stock performance or the reason for its decline. Pfizer (PFE) stock went down 1.49% because Arvinas and Pfizer announced updated clinical trial data for vepdegestrant (ARV-471), a potential treatment for breast cancer, which will be presented at the San Antonio Breast Cancer Symposium (SABCS).
	2023-11-27	-1.18 %
Pfizer Inc. (PFE) stock fell 1.18% due to a rough trading session in the stock market, with the S&P 500 and Dow Jones Industrial Average also experiencing declines. The stock's fall ended a five-day winning streak. The article discusses the Global Investment Summit in the UK, where the government is attracting financial support for UK projects. Prime Minister Rishi Sunak expressed positive momentum in the UK economy and announced investments worth around GBP30 billion. The stock price of Pfizer (PFE) went down by -1.18% last night, but the article does not provide a specific reason for this decline. Pfizer's stock (PFE) went down by -1.18% following the announcement of Arvinas, a biotechnology company, entering into a securities purchase agreement with institutional accredited investors, raising approximately $350 million through a private placement, causing a negative impact on the stock price.
	2023-11-24	+0.59 %
Ginkgo Bioworks, a company specializing in genetic engineering and artificial intelligence technology, has seen its stock decline due to substantial financial losses, but its collaborations with Pfizer and Google Cloud have the potential to drive innovation and increase its market value in the future. Pfizer (PFE) stock went up by 0.59% last night, and the reason for the increase is not mentioned in the article.
	2023-11-22	+0.07 %
The article does not provide any information or explanation about why Pfizer (PFE) stock went up.
	2023-11-21	+1.07 %
Pfizer (PFE) stock went up 1.07% last night after the European Patent Office declared a contested mRNA patent owned by Moderna invalid, giving a win to Pfizer and BioNTech in their patent dispute with Moderna. The article explains that stock markets today operate differently from previous generations due to the speed at which information spreads, and it does not provide a specific reason for the increase in Pfizer (PFE) stock. Pfizer's stock (PFE) went up by 1.07% last night, but no information explaining why is provided in the article.
	2023-11-20	+0.2 %
The article discusses how Moderna halted an early-stage clinical trial for its mRNA Epstein-Barr virus vaccine in adolescents after a participant developed a suspected case of myocarditis. This news may impact Moderna's stock, which has already experienced a decline due to lower sales of its Spikevax Covid vaccine. The halt of the trial raises questions about the safety of mRNA technology in vaccines, particularly in young people. As for why Pfizer's stock went up, this information is not provided in the article. Pfizer (PFE) stock went up 0.2% due to a positive trading session in the stock market, with the S&P 500 and Dow Jones Industrial Average also rising. Pfizer's stock went up by 0.2% due to increased demand for COVID-19 booster shots following the emergence of the Omicron variant.
	2023-11-17	+0.5 %
The article states that Pfizer (PFE) stock went up by 0.5% last night, and the reason for the increase is not mentioned in the summary. Despite a decline in the overall market and the slump in Pfizer Inc. (PFE) stock, Bristol Myers Squibb (BMY) experienced a downturn but had high earnings quality, increased investor activity, and attractive dividend payments, which may explain why the stock went up. Despite Pfizer's struggles with declining demand for its Covid-19 products, its stock went up by 0.5% last night, but the article does not provide a specific reason for this increase.
	2023-11-16	-1.39 %
The article states that Pfizer stock went down by -1.39% last night along with many other drug stocks, as most drug stocks have been out of favor in 2023 due to a decline in the S&P 500 Pharmaceuticals index. In a recent announcement, Pfizer revealed that it will lay off 781 employees at its facility in Gladstone, New Jersey, as sales of its Covid vaccine decline, with the company reducing its 2023 revenue estimate by $9 billion and implementing a cost-cutting initiative expected to save $3.5 billion. Pfizer (PFE) stock went down by 1.39% last night, and the reason for the decrease is not mentioned in the article.
	2023-11-15	+3.18 %
Pfizer's stock went up 3.18% because Anthos Therapeutics, a company backed by Blackstone, published positive results from phase 2 clinical trials for its anticoagulant drug abelacimab, which showed a 67% lower risk of bleeding compared to standard anticoagulants while still being effective at preventing clotting. CNBC's Jim Cramer stated that the overall earnings season has been positive, with many sectors performing well, but some stocks have been negatively affected by rising interest rates and concerns about weight loss drugs. However, Cramer was impressed with companies such as Microsoft, Alphabet, Apple, AMD, Intel, and homebuilders like Lennar, Pulte, DR Horton, and Toll Brothers, which reported solid results. Pfizer's stock went up due to positive earnings results. The article mentions that Pfizer's stock (PFE) went up by 3.18% last night, but it does not provide a specific reason for the increase in stock price.
	2023-11-14	+0.97 %
Pfizer's stock (PFE) went up by 0.97% due to a positive trading session in the stock market, where the S&P 500 and the Dow Jones Industrial Average also saw gains. Pfizer (PFE) stock went up by 0.97% last night, likely due to positive market conditions and the company's performance relative to its competitors. Pharmaceutical company Pfizer's stock (PFE) went up 0.97% last night due to an exclusive global licensing agreement with Jazz Pharmaceuticals for the development of drug candidates targeting neurological disorders, with a total deal value of up to $770.5 million including upfront and milestone payments.
	2023-11-13	-1.7 %
Pfizer's stock (PFE) went down by 1.7% last night, possibly due to an investigation into BioNTech (collaboration partner) regarding securities fraud or other unlawful business practices, which was triggered by a press release from BioNTech about Pfizer's non-cash charge for inventory write-offs and other charges related to COMIRNATY. The article reports that Pfizer (PFE) stock went down by 1.7% last night, but does not provide an explanation for the decrease in price. The article explains that Pfizer's stock has been declining due to a decrease in demand for its Covid-19 products, resulting in a significant decline in sales for its Paxlovid oral Covid treatment and Covid vaccine. This has caused Pfizer's stock to fall more than 50% since its peak in December 2021. The company's overall revenue and profits have also declined, with a 42% decrease reported in the first nine months of 2023 and a quarterly loss in October. Pfizer's market capitalization has lost $170 billion since December 2021, and the stock has posted a -40% return on investment this year. Other pharmaceutical stocks, including Moderna, BioNTech, and Johnson & Johnson, have also experienced declines. However, pharmaceutical companies Eli Lilly and Novo Nordisk have seen their stocks rise due to the popularity of their weight loss medications, making them the most valuable pharmaceutical companies in the world by market cap.
	2023-11-10	-0.67 %
The article does not provide information about Pfizer (PFE) stock specifically or why it may have gone down. The article discusses the recent approval of Eli Lilly's weight loss drug by the FDA, which has led to predictions of substantial sales and potential competition for Pfizer in the weight loss and diabetes sectors. The article does not provide a direct explanation for why Pfizer's stock went down.
	2023-11-09	-3.7 %
The article discusses Novavax's quarterly revenue, which exceeded expectations due to U.S. government grants, but also highlights that Novavax still has financial concerns and plans to cut costs to align with the smaller COVID-19 vaccine market, leading to a warning about their future. Pfizer's stock goes down as Novavax's positive performance highlights the smaller market for COVID-19 vaccines that Pfizer operates in, causing investors to reevaluate their expectations for Pfizer's revenue and growth potential. Pfizer (PFE) stock was down 3.7% last night, and the reason for the decline is not mentioned in the summary. Pfizer (PFE) stock went down by 3.7% due to disappointing earnings report and decreased sales of its Covid vaccine.
	2023-11-08	-1.38 %
Pfizer (PFE) stock went down by 1.38% due to an all-around mixed trading session in the stock market, as well as underperforming compared to some of its competitors like Johnson & Johnson and Merck & Co. Inc. The article discusses the financial results and guidance of Royalty Pharma plc for the third quarter of 2023. The article does not provide any information or explanation about Pfizer (PFE) stock going down. Pfizer's stock went down -1.38% last night, and it is speculated that the decline may be due to the upcoming release of data on its weight-loss pill, with investors waiting to see if it will have a positive impact on the company's stock.
	2023-11-07	+0.22 %
Pfizer (PFE) stock went up by 0.22% because the company announced 230 new jobs at two other Irish plants, despite cutting 100 jobs at its Newbridge plant due to a decrease in demand for its Covid medications. The decrease in sales of the Covid vaccine and antiviral Paxlovid led to a downgrade in predicted revenues for 2023. The article discusses how Pfizer's stock went up by 0.22% last night, but it does not provide an explanation as to why this occurred. Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, reported its third-quarter financial results and provided a corporate update, including upcoming data presentations at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, which could potentially support Arbutus' hypothesis that a functional cure for chronic hepatitis B virus (cHBV) can be achieved; the company also announced a reduction in its workforce as part of recent pipeline optimization efforts, and extended its cash runway into the first quarter of 2026; the article does not explain why the Pfizer (PFE) stock went up.
	2023-11-06	-0.26 %
The article discusses how Pfizer (PFE) stock went down by 0.26% last night, and attributes this decline to inventory write-downs by BioNTech (BNTX), Pfizer's collaboration partner, which resulted in lower revenues for the company. Pfizer (PFE) stock went down last night because BioNTech (BNTX), a company involved in the development of the Covid vaccine along with Pfizer, reported better-than-expected sales and a surprise profit during the September quarter. The article states that BioNTech has lowered its revenue target for 2023 due to lower demand for the COVID-19 vaccine made with Pfizer, resulting in a decrease in Pfizer's stock. The reduction in revenue was caused by write-downs reported by Pfizer, but the impact was less than initially anticipated. BioNTech is focusing on its development pipeline in oncology and has cut its research and development budget for 2023. Third-quarter revenues were lower than the previous year, but Pfizer and BioNTech have reported positive results in an early- to mid-stage trial for a vaccine that targets both flu and COVID-19.
	2023-11-03	+2.49 %
Pfizer (PFE) stock went up by 2.49% due to an announcement from the FDA advising healthcare providers to withdraw the correct volume of the Moderna COVID-19 vaccine to ensure the correct dose is administered, following incidents of incorrect dosing in children. The article discusses how Pfizer (PFE) stock increased by 2.49% last night and highlights the pharmaceutical industry's potential for generating significant returns for investors. The reason behind the stock's rise is not mentioned in the given information. The Pfizer (PFE) stock went up by 2.49% last night, but the article does not provide a reason for the increase.
	2023-11-02	-0.03 %
Pfizer (PFE) stock went down by 0.03% due to underperforming compared to its competitors and a weak outlook that disappointed investors. Pfizer presented its latest data on advancements in the treatment of hemophilia, sickle cell disease, and blood cancers at the American Society of Hematology (ASH) Annual Meeting and Exposition. The stock went down by -0.03% for reasons unrelated to the content of the article. The article states that Pfizer (PFE) stock went down by 0.03% last night, and the reason for the decline is not mentioned in the article.
	2023-11-01	-0.16 %
Pfizer's stock went down by -0.16% after the company confirmed layoffs at its New Jersey facility due to poor sales of Covid vaccines, although it has promising non-Covid products and potential acquisitions in the pipeline. Pfizer (PFE) stock went down by -0.16% last night, but this article does not provide any information on why the stock declined.
	2023-10-31	+0.03 %
The article discusses the recent performance of Pfizer (PFE) stock, noting that it was up 0.03% last night, but does not provide a specific reason for the increase. Pfizer Inc. reported a wider-than-expected third-quarter loss due to weakness in COVID products, but the stock went up by 0.03%. The company attributed the increase to the removal of uncertainty through a supply agreement with the U.S. government, expectations of improved vaccination and treatment rates, and promising breakthroughs in its pipeline. Additionally, Pfizer highlighted its new product launches, including the recently launched Abrysvo vaccine, and its ongoing pipeline developments. The company's acquisition of Seagen Inc. is expected to close in the near future, and analysts are eagerly awaiting Phase 2 trial results for Pfizer's investigational obesity pill. The article states that Pfizer (PFE) stock went up by 0.03% last night, and it does not mention the reason for the increase.
	2023-10-30	+1.46 %
Pfizer (PFE) stock went up by 1.46% last night, as Wall Street rallied and all three major U.S. stock indexes surged higher, driven by positive earnings reports and anticipation of the Federal Reserve's interest rate decision. Pfizer (PFE) stock went up by 1.46% last night, possibly due to positive investor sentiment and expectations of strong quarterly results. A train accident in Andhra Pradesh resulted in the derailment of bogies, causing casualties and injuries, with Prime Minister Narendra Modi announcing financial assistance for the affected individuals.
	2023-10-27	-3.37 %
The article announces that Robin Evers, Head of Global Regulatory Affairs & Global Safety at Novo Nordisk, has joined the Board of Directors at Orexo AB. The reason for Pfizer's stock going down is not mentioned in the article. The article announces that Fortune Brands Innovations, Inc. has appointed Kristin Papesh as Executive Vice President and Chief Human Resources Officer, and Sheri Grissom will transition to solely focus on leading the Company's Transformation Management Office as Chief Transformation Officer. The reason for the decline in Pfizer (PFE) stock is not mentioned in the article. The article discusses upcoming events such as central bank meetings, corporate earnings reports, and market trends. It does not specifically mention why Pfizer (PFE) stock went down.
	2023-10-26	+1.4 %
The article discusses WPP's third-quarter trading update, which shows a 1.8% decrease in revenue but a 2.3% increase in like-for-like revenue. The CEO of WPP, Mark Read, attributes the lower-than-expected performance to cautious spending trends seen in the second quarter, particularly from technology clients. However, Read highlights that WPP continues to win new business and is focused on evolving its services and simplifying its business to better serve clients and maximize returns on investments in AI and technology. The article also mentions the creation of the world's largest integrated creative agency, VML, and the simplification of GroupM's operating model as strategic initiatives to strengthen WPP's client proposition. As for why Pfizer (PFE) stock went up, the article does not provide any information on that topic. The article discusses the ongoing challenges in the COVID-19 vaccine rollout in Alberta, with some pharmacies experiencing problems with their vaccine orders. Specifically, some pharmacies have reported not receiving any doses of the Pfizer vaccine in their deliveries, despite the government indicating that they have enough stock. The lack of Pfizer stock poses challenges for those who prefer or are "brand loyal" to that particular shot. The Alberta government announced an increase in the ordering limit for pharmacies from 100 doses to 350 doses per week. However, some pharmacists feel that they could vaccinate more people if they were given more vaccine supply. The article does not provide a reason for the increase in the Pfizer (PFE) stock. Pfizer's stock went up 1.4% because positive data from an early trial of their combined Covid-19 and influenza vaccine was released, sparking a competitive race with other vaccine manufacturers.

1
500 / page